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TUMOUR INHIBITORY TRIAZENES.
D. E. V. WILMAN, Chester Beatty Research
Institute, London.
5-(3, 3- Dimethyl-l-triazeno) imidazole-4-
carboxamide (DIC) is a well known anti-
tumour agent undergoing clinical trial. It
has the disadvantage of being very photo-
sensitive. The related aryltriazenes, how-
ever, do not decompose in this fashion
although they are acid labile, to an extent
dependent on the ring substituents.
In the case of 1-aryl-3, 3-dialkyltriazenes,
the ring substituents have no marked effect
on the activity towards the TLX5 lymphoma.
Replacement of both methyl groups by ethyl
orisopropyl groups leads to inactivity, where-
as if only one is replaced activity is retained.
Microsomal metabolism experiments suggest
that this is due to enzymic dealkylation to
form the monoalkyl derivative.
Metabolism of I-aryl-3-methyl-3-alkyl-
triazenes gives the monomethyltriazene.
Monomethyltriazenes are more acid labile
and the activity of this metabolite is depen-
dent on its half-life and hence the ring
substituent. The dialkyltriazenes probably
act as a slow release form of the monoalkyl
metabolite, which is the active species.
UPTAKE OF SULPHONAMIDES BY
ANIMAL TUMOURS AND THE ANTI-
TUMOUR PROPERTIES OF TRIA-
ZENES DERIVED FROM THEM. G.
ABEL, Chester Beatty Research Institute,
London.
The distribution of several sulphonamides
in various tissues of the mouse has been
examined. When compared with their con-
centration in the liver, several ofthe sulphon-
amides showed preferential deposition in the
PC6 plasma cell tumour. No correlation was
found between the tumour/liver concen-
tration ratio and pKa, Po or solubility in
phosphate buffer. The corresponding 3,
3-dimethyltriazenes were synthesized and
tested for their anti-tumour activity. Com-
pared with a standard phenyl triazene, 2 of
them had superior anti-tumour properties.
The triazene prepared from sulphadiazine
was labelled (14C) in the aryl moiety and
(3H) in the methyl groups and its tissue
distribution studied. No selective concen-
tration in the tumour was found.
Studies ofthe metabolism ofthe triazenes
suggest that the active metabolite is the
monomethyl analogue which can decompose
chemically into alkylating moieties.
THE ROLE OF ALKALINE PHOS-
PHATASE IN THE RELEASE OF p-
HYDROXY ANILINE MUSTARD FROM
ITS PHOSPHATE CONJUGATE. P.
WORKMAN, J. A. DOUBLE and C. R. BALL,
Department of Cancer Research, University
of Leeds.
Para-hydroxy aniline mustard phosphate
(AM-O-phos) was among the esters of
p-hydroxy aniline mustard (AM-OH) synthes-
ized with the aim that such conjugates would
exhibit a specific cytotoxic effect, via the
release of AM-OH, towards tumours contain-
ing high levels of the appropriate decon-
jugating enzymes (Bukhari, Everett and
Ross, Biochem. Pharmac., 1971, 21, 963).
Subsequently AM-O-phos was showrh to be a
substrate for selected phosphatases (Ball and
Double, Biochem. Pharmac., 1974, 23, 3173).
In this work the cytotoxicity of AM-O-phos
in HeLa cultures was studied in relation to
the phosphatases of this cell line. The
results are consistent with the view that the
uptake of AM-OH is dependent on the
activity of alkaline phosphatase, of the
carcino placental type, located in the plasma
membrane. No such dependence on acid
phosphatase activity was observed. The
cell culture model has also allowed the
importance of extracellular phosphatase
activity to be assessed.
HORMONES IN BREAST CANCER
PATIENTS ON TAMOXIFEN. M. P.
GOLDER, M. E. A. PHILLIPS, M. BAUM, K.
GRIFFITHS, D. R. FAHMY, J. M. HENK, V.
JONES AND P. E. PREECE, South Wales and
Monmouthshire Radiotherapy Centre,
Velindre Hospital, and Tenovus Institute for
Cancer Research, Department of Surgery,
Welsh National School of Medicine, Cardiff.
Tamoxifen (20 mg) has been given twice
daily to 30 consecutive post-menopausal
women with advanced breast cancer. Pro-
lactin, oestradiol 17f, growth, luteinizing and
follicle stimulating hormones have been
assayed on plasma taken before and at
regular intervals during treatment. By the
criteria of Forrest (in Clinical Management of
Advanced Breast Cancer. Eds. Joslin and
Gleave, Cardiff: Alpha Omega Alpha Publish-